Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cancer progression is characterized by dysregulated G1/S phase transition mediated by CDK4/6-dependent Rb protein phosphorylation. Although CDK4/6 degraders show encouraging anti-tumor efficacy, it is highly desired to develop strategies to spatiotemporally control the release of active CDK4/6 degraders to further reduce adverse effects. In this study, we employ an optochemical strategy for CDK4/6 degradation by caging the CRBN ligand with a photoremovable protecting group. Light irradiation at 365 nm triggers photocleavage, thereby inducing CDK4/6 degradation via the ubiquitin-proteasome system. The resultant G1-phase arrest demonstrates spatial and temporal control over cell-cycle progression, reducing off-target effects of current therapies. This light-controlled system allows spatiotemporal CDK4/6 degradation and G1 cell-cycle arrest, providing a promising strategy to enhance specificity for cancer treatment and fundamental biological research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398220PMC
http://dx.doi.org/10.1016/j.isci.2025.113304DOI Listing

Publication Analysis

Top Keywords

cdk4/6 degradation
16
cdk4/6 degraders
8
cdk4/6
6
optochemical control
4
control cell
4
cell cycle
4
cycle regulating
4
regulating cdk4/6
4
degradation
4
degradation cancer
4

Similar Publications

Background: Although some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(-) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights.

Materials And Methods: A literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.

View Article and Find Full Text PDF

Background: Apixaban and rivaroxaban are oral direct factor Xa inhibitors, primarily eliminated through CYP3A4-mediated metabolism and direct intestinal excretion. Previous studies suggest that palbociclib, a CDK4/6 inhibitor, may increase the systemic exposure of these anticoagulants; however, the specific pharmacokinetic mechanisms remain unclear. This study aims to evaluate the effects of palbociclib on the pharmacokinetics of apixaban and rivaroxaban using a rat model to optimize combined drug regimens.

View Article and Find Full Text PDF

Cancer progression is characterized by dysregulated G1/S phase transition mediated by CDK4/6-dependent Rb protein phosphorylation. Although CDK4/6 degraders show encouraging anti-tumor efficacy, it is highly desired to develop strategies to spatiotemporally control the release of active CDK4/6 degraders to further reduce adverse effects. In this study, we employ an optochemical strategy for CDK4/6 degradation by caging the CRBN ligand with a photoremovable protecting group.

View Article and Find Full Text PDF

Cancer is characterized by abnormal cell proliferation. Cyclins and cyclin-dependent kinases (CDKs) have been recognized as essential regulators of the intricate cell cycle, orchestrating DNA replication and transcription, RNA splicing, and protein synthesis. Dysregulation of the CDK pathway is prevalent in the development and progression of human cancers, rendering cyclins and CDKs attractive therapeutic targets.

View Article and Find Full Text PDF

Epithelial-to-mesenchymal transition (EMT) is a cellular process important for numerous developmental processes, wound healing and cancer progression. In the context of heterogenous nature of cancer, EMT occurs at the forefront of tumor invasion, although the precise molecular mechanisms governing its spatial dynamics remain unclear. This study aimed to explore the diverse responses to EMT in monolayer cell cultures of MCF10A epithelial cell with induction of Zinc-finger E-box binding homeobox 1 (ZEB1), an EMT-inducing transcription factor.

View Article and Find Full Text PDF